Marshall Edwards, Inc.(Nasdaq : MSHL) shares boosted 13.3% to $1.70, on volume of 45,250 shares, shy of its all-day average of 57,758, after it announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

Microsoft Corporation (Nasdaq: MSFT) dealt in 26.2 million shares, making it one of the leaders, but still short of its average of 58.7 million. Shares for the computer behemoth advanced 2.1% to $25.33, amid strength in the tech industry.

Majestic Capital Inc. (Nasdaq: MAJC) lost its parachute and dropped 72.7% in price Monday to $1.18, on volume of 1.3 million shares, towering over a daily average of around 5,300, as the company mulls bankruptcy following a termination of a merger agreement with Bayside Capital Partners.